Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer

Intellia Therapeutics, Inc., a company focused on developing curative therapies leveraging CRISPR-based technologies, and ONK Therapeutics Ltd., a company dedicated to developing optimally engineered NK cell therapies to treat cancer, announced a licensing and collaboration agreement.